Acute myeloid/T-lymphoblastic leukaemia (AMTL): a distinct category of acute leukaemias with common pathogenesis in need of improved therapy.
Acute myeloid/T-lymphoblastic leukaemia (AMTL): a distinct category of acute leukaemias with common pathogenesis in need of improved therapy.
复制标题
DOI：
10.1111/bjh.15129
复制
发表时间：
2018-03
影响因子：
6.5
通讯作者：
Kentsis A
中科院分区：
文献类型：
--
作者：
Gutierrez A;Kentsis A
急性白血病分类的进展已经改善了相当一部分患者的预后。然而，化疗耐药性仍然是急性白血病特定亚群的主要问题。在这里，我们提出，急性白血病的分子上不同的亚型，具有共同的髓细胞和T细胞淋巴母细胞的功能，我们称之为急性髓细胞/T淋巴母细胞白血病（AMTL），分为3个诊断类别，由于被认为是定义的髓细胞和T淋巴谱系，如髓过氧化物酶和CD 3的标志物的可变表达。这一拟议的诊断组得到以下方面的支持：i）在早期T细胞淋巴发育期间保留的髓样分化潜能，ii）认识到某些急性髓性白血病（AML）病例具有T细胞发育的标志，如T细胞受体基因重排，iii）AML和T细胞急性淋巴细胞白血病（T-ALL）亚群中的常见基因突变，包括WT 1、PHF 6、RUNX 1和BCL 11 B。该建议的诊断实体与早期T细胞前体（ETP）T-ALL和T细胞/骨髓混合表型急性白血病（MPAL）重叠，还包括目前归类为AML的白血病亚组，具有T淋巴细胞发育特征。AMTL作为一个独特的实体的拟议分类将使更精确的前瞻性诊断，并允许开发改进的治疗方法的患者的治疗是不充分的与目前的方法。
Advances in the classification of acute leukaemias have led to improved outcomes for a substantial fraction of patients. However, chemotherapy resistance remains a major problem for specific subsets of acute leukaemias. Here, we propose that a molecularly distinct subtype of acute leukaemia with shared myeloid and T cell lymphoblastic features, which we term acute myeloid/T-lymphoblastic leukaemia (AMTL), is divided across 3 diagnostic categories owing to variable expression of markers deemed to be defining of myeloid and T-lymphoid lineages, such as myeloperoxidase and CD3. This proposed diagnostic group is supported by i) retained myeloid differentiation potential during early T cell lymphoid development, ii) recognition that some cases of acute myeloid leukaemia (AML) harbour hallmarks of T cell development, such as T-cell receptor gene rearrangements and iii) common gene mutations in subsets of AML and T cell acute lymphoblastic leukaemia (T-ALL), including WT1, PHF6, RUNX1 and BCL11B. This proposed diagnostic entity overlaps with early T cell precursor (ETP) T-ALL and T cell/myeloid mixed phenotype acute leukaemias (MPALs), and also includes a subset of leukaemias currently classified as AML with features of T-lymphoblastic development. The proposed classification of AMTL as a distinct entity would enable more precise prospective diagnosis and permit the development of improved therapies for patients whose treatment is inadequate with current approaches.
登录
查看更多内容
影响因子：
28.2
作者：
Pan R;Hogdal LJ;Benito JM;Bucci D;Han L;Borthakur G;Cortes J;DeAngelo DJ;Debose L;Mu H;Döhner H;Gaidzik VI;Galinsky I;Golfman LS;Haferlach T;Harutyunyan KG;Hu J;Leverson JD;Marcucci G;Müschen M;Newman R;Park E;Ruvolo PP;Ruvolo V;Ryan J;Schindela S;Zweidler-McKay P;Stone RM;Kantarjian H;Andreeff M;Konopleva M;Letai AG
通讯作者：
Letai AG
影响因子：
82.9
作者：
通讯作者：
--
DOI：
10.1038/nrg2485
发表时间：
2009-01
期刊：
Nature reviews. Genetics
影响因子：
--
作者：
通讯作者：
--
影响因子：
28.2
作者：
Ogiwara, Hideaki;Sasaki, Mariko;Kohno, Takashi
通讯作者：
Kohno, Takashi
影响因子：
51.1
作者：
Coustan-Smith, Elaine;Mullighan, Charles G.;Onciu, Mihaela;Behm, Frederick G.;Raimondi, Susana C.;Pei, Deqing;Cheng, Cheng;Su, Xiaoping;Rubnitz, Jeffrey E.;Basso, Giuseppe;Biondi, Andrea;Pui, Ching-Hon;Downing, James R.;Campana, Dario
通讯作者：
Campana, Dario